Valuation
- Market cap
- 507,940,000
- Revenue TTM
- $1,450,000
- Net income TTM
- $-119,440,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -8,237.24%
- Debt to equity
- 0.00
Trading
- Volume
- 586,300
- Avg volume
- 250,324
- Day's range
- $8.53 – $8.83
- Shares out
- 57,984,000
- Stochastic %K
- 9%
- Beta
- 0.62
- Analysts
- Strong Sell
- Price target
- $37.90
Company profile
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2...
Show more
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 41 41 711 3960
- Website
- https://oculis.com
- Address
- Bahnhofstrasse 20, Zug, Switzerland
Latest news
No headlines yet.
